Biocon Limited has informed the Exchange regarding a press release dated Jun 30, 2025, titled "Biocon Biologics Expands Insulin Access in Malaysia Over 100 Mn Cartridges of rh-Insulin Supplied to Health Ministry; 345,000+ patients served".
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biocon's subsidiary Biocon Biologics Ltd. (BBL), through its Malaysian arm Biocon Sdn. Bhd., has supplied over 100 million cartridges of recombinant human insulin (rh-insulin) to Malaysia's Ministry of Health, serving more than 345,000 diabetes patients since entering the market in 2016. The milestone is supported by a USD 600 million cumulative investment since 2011 in a state-of-the-art insulin manufacturing facility in Johor, Malaysia, recognized as the first and largest integrated insulin manufacturer in the country. The company partners with Duopharma Marketing Sdn. Bhd. for distribution. Globally, Biocon Biologics has cumulatively supplied 9.2 billion doses of rh-Insulin and Insulin Glargine and ranks among the Top 3 players worldwide in these segments, serving patients across 120+ countries.
This is a positive operational update highlighting Biocon Biologics' strong international footprint and long-term government partnerships, reinforcing its biosimilars growth story. However, no new financial figures or order values were disclosed, so near-term stock impact may be limited to sentiment.